Alivus Life Sciences

Glenmark Life Sciences is a prominent developer and manufacturer of affordable, high-quality Active Pharmaceutical Ingredients (APIs), spun-off from Glenmark Pharmaceuticals in 2019 to establish an independent API business. Its core vision is to become the most valued API player in the industry by delivering affordable, high-quality APIs through the application of science and engineering. The company's strategy focuses on selecting APIs that involve high-end chemistry, which creates a significant entry barrier for potential competitors in the market. It has established strong partnerships with leading global generic pharmaceutical companies operating in highly regulated markets like the US, Canada, Japan, Europe, and India. The company's growth strategy includes expanding its geographic reach, diversifying its client portfolio, and increasing its Contract Development and Manufacturing Organisation (CDMO) business. The company possesses a strong portfolio of 151 molecules, which collectively target a front-end market value of approximately USD 180 billion.;